GlyTherix Partners with SHINE Technologies to Advance Targeted Radiotherapy for Aggressive Cancers

GlyTherix Ltd, an Australian company focused on developing targeted radiotherapy for solid tumors, has announced a new global clinical supply agreement with SHINE Technologies. Based in Janesville, Wisconsin, SHINE Technologies is a leader in next-generation fusion technology and North America's largest producer of non-carrier added lutetium-177 (n.c.a. Lu-177) chloride. According to the agreement, SHINE will supply its n.c.a. Lu-177 chloride, known as Ilumira, for use in GlyTherix's clinical trials aimed at treating aggressive and invasive cancers.

GlyTherix’s innovative radiotherapy involves combining Lu-177 with a molecule that targets Glypican-1, a protein often found in aggressive cancers, to deliver localized radiation to tumors while minimizing damage to healthy tissues. This approach, embodied in GlyTherix's 177Lu-DOTA-Miltuximab®, is set to enter Phase Ib trials in early 2025. These trials will focus on tumors expressing Glypican-1, which is associated with several aggressive cancers including prostate, pancreatic, bladder, lung, glioblastoma, and ovarian cancer.

SHINE's Ilumira is produced in its Cassiopeia facility in Janesville, the largest facility of its kind in North America. This facility initially has a production capacity of 100,000 doses per year, with the potential to scale up to 200,000 doses annually. The facility's capability ensures a reliable supply of high-quality n.c.a. Lu-177, essential for GlyTherix’s clinical trials and the broader U.S. market.

GlyTherix CEO Dr. Brad Walsh emphasized SHINE's pivotal role in the radiopharmaceutical supply chain, particularly in serving the U.S. market. He highlighted that the supply agreement with SHINE complements GlyTherix’s broader global supplier network, which also includes a clinical supply agreement with the Australian Nuclear Science and Technology Organization (ANSTO).

Greg Piefer, SHINE’s founder and CEO, expressed enthusiasm for the partnership, noting that GlyTherix’s pioneering approach in targeted radiotherapy could revolutionize cancer treatment for patients with limited options. He underscored SHINE’s commitment to providing a consistent supply of high-quality Ilumira to support GlyTherix's groundbreaking work.

This collaboration between GlyTherix and SHINE represents a significant milestone in advancing targeted radiotherapy. The partnership aligns with SHINE’s mission to leverage nuclear technology for human health and underscores its role in enhancing cancer treatment globally. The evolving production capabilities and vertical integration of Lu-177 supply at SHINE highlight the potential to transform therapeutic approaches for hard-to-treat cancers, offering new hope to patients.

SHINE Technologies, headquartered in Janesville, Wisconsin, stands out for its innovative fusion-based technologies that combine safety, cost-efficiency, and environmental responsibility. The company is not only a leader in producing non-carrier-added lutetium-177 but is also pursuing advancements in producing molybdenum-99, a critical diagnostic tool for detecting heart disease and cancer. Furthermore, SHINE is exploring the complex challenge of nuclear waste recycling, showcasing its commitment to sustainable energy solutions and technological advancements.

GlyTherix Ltd specializes in developing antibody radiopharmaceuticals targeting solid tumors. Their lead product, Miltuximab®, targets Glypican-1 in various cancers and has completed a 'First-in-Human' trial with no drug-related adverse effects. The company is preparing for a Phase Ib trial and is open to partnerships with larger biotech and pharmaceutical firms to further its mission of providing new treatments for patients with limited options.